Navigation Links
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Date:9/8/2009

ted antibodies in combination with a wide range of anti-cancer agents, including many commonly prescribed chemotherapeutic drugs. This patent was granted to the University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

The Phase II trial of bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients has a Simon two-stage design. In the first stage, 15 patients with advanced breast cancer were enrolled and treated with the combination regimen. Nine of the 14 (64%) evaluable patients in this cohort demonstrated an objective tumor response according to RECIST criteria, exceeding the pre-specified primary efficacy endpoint needed to expand enrollment in the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall.

"Completion of patient enrollment in our second Phase II breast cancer study marks another milestone for the bavituximab cancer program, with two of our three ongoing Phase II trials now having completed enrollment," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "We believe the rapid enrollment experienced in all three of these trials is representative of the enthusiasm of our clinical investigators as well as the need for improved cancer therapies. We look forward to reporting further data from these studies in the upcoming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. They may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... investment in the development and manufacture of highly valued cardiac markers used in ... team's extensive expertise with protein chemistry has led to the development and commercialization ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... CRANBURY, N.J., March 7, 2012 Palatin Technologies, Inc. (NYSE ... presenting at the 24th Annual ROTH OC Growth Stock Conference ... The conference will be held at the Ritz Carlton Laguna ... Ph.D., President and Chief Executive Officer of Palatin Technologies, will ...
... LONGNAN CITY, China, March 6, 2012   Apexigen, Inc., ... Biological Pharmaceutical Co., Ltd. (GDBP), which is listed ... they entered into a collaboration to grant an ... APX004 in China.   APX004 is a humanized monoclonal ...
... Drexel University,s Dr. Yury Gogotsi has given the engineering ... the electrodes of supercapacitors the low-cost, lightweight energy ... other applications. In a piece published in the March ... his collaborators from universities in France and England, take ...
Cached Biology Technology:Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 2Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 3Drexel's Gogotsi and team advance understanding of energy storage mechanisms in Nature Materials 2
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/6/2015)... , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking Integration ... Moverio BT-200 see-through head mounted display and on SMI,s ... quality and efficiency is brought to personalized visualization and ... first time, professionals and researchers can integrate gaze, and ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... LAS VEGAS , Oct. 7, 2013 ValidSoft, ... and transaction verification solutions, and a wholly owned subsidiary ... integrated its secure mobile commerce technology with Spindle,s new ... the Money2020 ( www.money2020.com ) conference being held from ...
... SAN DIEGO , Oct. 9, 2013  Biocom, the association ... community, today announced the endorsement of Nathan Fletcher ... . (Logo: http://photos.prnewswire.com/prnh/20130228/LA69104LOGO ) "A ... of the three major candidates.  Although all three would be ...
... SAN DIEGO , Oct. 14, 2013 Trovagene, ... cell-free molecular diagnostics, announced today that two abstracts (#B175 ... novel, non-invasive cancer mutation monitoring platform will be presented ... on Molecular Targets and Cancer Therapeutics in ...
Cached Biology News:ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 2ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 3ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 4ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 5Biocom Announces 2013 San Diego Mayoral Primary Endorsement 2Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference 2Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference 3
... 2500ml narrow mouth PYREX low form culture flask is ... to volume ratio. This flask has a heavy beaded ... marking spot. The neck O.D. is 38mm and takes ... use this flask on a heat source smaller than ...
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
... Pyronin Y is most widely used ... selectively and differentially stain nucleic acids ... dichromatic dye solution, Pyronin Y stains ... DNA green. Chem comp: ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Biology Products: